How a new CEO has been trying to position Editas to execute on the promise of CRISPR
- blonca9
- Aug 2, 2023
- 1 min read
Gilmore O’Neill is working to inject stability and focus at Editas as the company aims to execute on both ex-vivo and in-vivo crispr gene therapies.